Administration and effects of beta blockers and oxandrolone in severely burned adults: a post hoc analysis of the RE-ENERGIZE trial

Abstract

Background: Prospective randomized trials in severely burned children have shown the positive effects of oxandrolone (OX), beta blockers (BB) and a combination of the two (BBOX) on hypermetabolism, catabolism and hyperinflammation short-and long-term post-burn. Although data on severely burned adults are lacking in comparison, BB, OX and BBOX appear to be commonly employed in this patient population. In this study, we perform a secondary analysis of an international prospective randomized trial dataset to provide descriptive evidence regarding the current utilization patterns and potential treatment effects of OX, BB and BBOX. Methods: The RE-ENERGIZE (RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury, NCT00985205) trial included 1200 adult patients with severe burns. We stratified patients according to their receipt of OX, BB, BBOX or none of these drugs (None) during acute hospitalization. Descriptive statistics describe the details of drug therapy and unadjusted analyses identify predisposing factors for drug use per group. Association between OX, BB and BBOX and clinical outcomes such as time to discharge alive and 6-month mortality were modeled using adjusted multivariable Cox regressions. Results: More than half of all patients in the trial received either OX (n = 138), BB (n = 293) or BBOX (n = 282), as opposed to None (n = 487, 40.6%). Per study site and geographical region, use of OX, BB and BBOX was highly variable. Predisposing factors for the use of OX, BB and BBOX included larger total body surface area (TBSA) burned, higher acute physiology and chronic health evaluation (APACHE) II scores on admission and younger patient age. After adjustment for multiple covariates, the use of OX was associated with a longer time to discharge alive [hazard ratio (HR) 0.62, confidence interval (CI) (0.47–0.82) per 100% increase, p = 0.001]. A higher proportion of days on BB was associated with lower in-hospital-mortality (HR: 0.5, CI 0.28–0.87, p = 0.015) and 6-month mortality (HR: 0.44, CI 0.24–0.82, p = 0.01). Conclusions: The use of OX, BB and BBOX is common within the adult burn patient population, with its use varying considerably across sites worldwide. Our findings found mixed associations between outcomes and the use of BB and OX in adult burn patients, with lower acute and 6-month-mortality with BB and longer times to discharge with OX. Further research into these pharmacological modulators of the pathophysiological response to severe burn injury is indicated.

Keywords

Burns / Critical illness / Hypermetabolism / Oxandrolone / Beta blocker

References

[1] Forjuoh SN.Burns in low-and middle-income countries: a review of available literature on descriptive epidemiology, risk factors, treatment, and prevention. Burns. 2006; 32: 529-37.

[2] Monk DN, Plank LD, Franch-Arcas G, Finn PJ, Streat SJ, Hill GL. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. Ann Surg. 1996; 223: 395-405.

[3] Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Gauglitz GG, Kulp GA, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care. 2007; 11: R90.

[4] Thakkar RK, Penatzer J, Simon S, Steele L, Fabia R, Groner JI, et al. Measures of adaptive immune function predict the risk of nosocomial infection in Pediatric burn patients. J Burn Care Res Off Publ Am Burn Assoc. 2022; 43: 1416-25.

[5] Tapking C, Popp D, Herndon DN, Branski LK, Hundeshagen G, Armenta AM, et al. Cardiac dysfunction in severely burned patients: current understanding of etiology, pathophysiology, and treatment. Shock. 2020; 53: 669-78.

[6] Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, et al. The pathophysiologic response to severe burn injury. Ann Surg. 2008; 248: 387-401.

[7] Hassoun-Kheir N, Henig O, Avni T, Leibovici L, Paul M. The effect of β-blockers for burn patients on clinical outcomes: systematic review and meta-analysis. J Intensive Care Med. 2021; 36: 945-53.

[8] Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001; 345: 1223-9.

[9] Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR. Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Ann Surg. 1988; 208: 484-92.

[10] Herndon DN, Rodriguez NA, Diaz EC, Hegde S, Jennings K, Mlcak RP, et al. Long-term propranolol use in severely burned Pediatric patients: a randomized controlled study. Ann Surg. 2012; 256: 402-11.

[11] Williams FN, Herndon DN, Kulp GA, Jeschke MG. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery. 2011; 149: 231-9.

[12] Mohammadi AA, Bakhshaeekia A, Alibeigi P, Hasheminasab MJ, Tolide-ei HR, Tavakkolian AR, et al. Efficacy of propranolol in wound healing for hospitalized burn patients. J Burn Care Res. 2009; 30: 1013-7.

[13] Garg A, Garg S, She RW. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation. Burns. 2011; 37: 1150-3.

[14] Reeves PT, Herndon DN, Tanksley JD, Jennings K, Klein GL, Mlcak RP, et al. Five-year outcomes after long-term OXANDROLONE administration in severely burned children: a randomized clinical trial. Shock Augusta Ga. 2016; 45: 367-74.

[15] Porro LJ, Herndon DN, Rodriguez NA, Jennings K, Klein GL, Mlcak RP, et al. Five-year outcomes after Oxandrolone Administration in Severely Burned Children: a randomized clinical trial of safety and efficacy. J Am Coll Surg. 2012; 214: 489-502.

[16] Przkora R, Jeschke MG, Barrow RE, Suman OE, Meyer WJ, Finnerty CC, et al. Metabolic and hormonal changes of severely burned children receiving long-term Oxandrolone treatment. Ann Surg. 2005; 242: 384-91.

[17] Ring J, Heinelt M, Sharma S, Letourneau S, Jeschke MG. Oxandrolone in the treatment of burn injuries: a systematic review and meta-analysis. J Burn Care Res. 2020; 41: 190-9.

[18] Wolf SE, Edelman LS, Kemalyan N, Donison L, Cross J, Underwood M, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res Off Publ Am Burn Assoc. 2006; 27: 131-9 discussion 140-141.

[19] Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care. 2000; 15: 12-7.

[20] Chao T, Porter C, Herndon DN, Siopi A, Ideker H, Mlcak RP, et al. Propranolol and Oxandrolone therapy accelerated muscle recovery in burned children. Med Sci Sports Exerc. 2018; 50: 427-35.

[21] Herndon DN, Capek KD, Ross E, Jay JW, Prasai A, El Ayadi A, et al. Reduced Postburn hypertrophic scarring and improved physical recovery with yearlong Administration of Oxandrolone and Propranolol. Ann Surg. 2018; 268: 431-41.

[22] Van Zanten AR, Sztark F, Kaisers UX, Zielmann S, Felbinger TW, Sablotzki AR, et al. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA. 2014; 312: 514-24.

[23] Heyland DK, Wischmeyer P, Jeschke MG, Wibbenmeyer L, Turgeon AF, Stelfox HT, et al. A RandomizEd trial of ENtERal glutamine to minimIZE thermal injury (the RE-ENERGIZE trial): a clinical trial protocol. Scars Burns Heal. 2017; 3: 205951311774524.

[24] Heyland DK, Wibbenmeyer L, Pollack JA, Friedman B, Turgeon AF, Eshraghi N, et al. A randomized trial of enteral glutamine for treatment of burn injuries. N Engl J Med. 2022; 387: 1001-10.

[25] Flores O, Stockton K, Roberts JA, Muller MJ, Paratz JD. The efficacy and safety of adrenergic blockade after burn injury: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2016; 80: 146-55.

[26] LeCompte MT, Rae L, Kahn SA. A survey of the use of propranolol in burn centers: who, what, when, why. Burns. 2017; 43: 121-6.

[27] Brown DA, Gibbons J, Honari S, Klein MB, Pham TN, Gibran NS. Propranolol dosing practices in adult burn patients: implications for safety and efficacy. J Burn Care Res. 2016; 37: e218-26.

[28] Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011; 6: e21245.

[29] Lesser GJ, Case D, Ottery F, McQuellon R, Choksi JK, Sanders G, et al. A phase III randomized study comparing the effects of oxandrolone (ox) and megestrol acetate (meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol. 2008; 26: 9513-3.

[30] Tchekmedyian S, Fesen M, Price LM, Ottery FD. Ongoing placebo-controlled study of oxandrolone in cancer-related weight loss. Int J Radiat Oncol Biol Phys. 2003; 57: S283-4.

[31] Herndon DN, Wilmore DW, Mason AD, Jr. Development and analysis of a small animal model simulating the human postburn hypermetabolic response. J Surg Res. 1978; 25: 394-403.

[32] Pereira C, Murphy K, Herndon D. Outcome measures in burn care: is mortality dead? Burns. 2004; 30: 761-71.

[33] Li H, Guo Y, Yang Z, Roy M, Guo Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: a systematic review and meta-analysis. Burns J Int Soc Burn Inj. 2016; 42: 717-27.